Skip to main content
. 2022 Aug 9;6(24):6219–6227. doi: 10.1182/bloodadvances.2022008028

Figure 3.

Figure 3.

Survival analysis. Time to clinical response in patients treated with rituximab + PEX, with or without the addition of caplacizumab (n = 111∗). (It should be noted that all patients also received corticosteroids.) ∗Seven patients were lost to follow-up: 2 patients receiving rituximab and 5 patients receiving rituximab and caplacizumab. Capla, caplacizumab.